

---

**SENATE COMMITTEE AMENDMENTS**

2026 Regular Session

Amendments proposed by Senate Committee on Insurance to Reengrossed House Bill No. 870 by Representative Turner

---

1 AMENDMENT NO. 1

2 On page 1, line 4, after "practices;" insert "to provide for certain notices;"

3 AMENDMENT NO. 2

4 On page 2, between lines 8 and 9, insert the following:

5 "(5) "Net cost calculation" means the wholesale acquisition cost minus all  
6 rebates, discounts, and fees."

7 AMENDMENT NO. 3

8 On page 2, at the beginning of line 9, change "(5)" to "(6)"

9 AMENDMENT NO. 4

10 On page 2, at the beginning of line 12, change "(6)" to "(7)"

11 AMENDMENT NO. 5

12 On page 2, at the beginning of line 17, change "(7)" to "(8)"

13 AMENDMENT NO. 6

14 On page 3, after line 26, insert the following:

15 "D.(1) A health insurance issuer shall notify the commissioner in writing  
16 within thirty days if the health insurance issuer opts to utilize the net cost calculation  
17 for a branded prescription drug in a drug formulary, in lieu of placing a generic or  
18 biosimilar on the drug formulary.

19 (2) For each National Drug Code (NDC), the notification shall provide the  
20 following information for both the branded prescription drug and any available  
21 generic or biosimilar:

22 (a) Wholesale acquisition cost.

23 (b) Net cost.

24 (3) The health insurance issuer shall provide the branded prescription drug  
25 cost-sharing amount and the cost-sharing amount if the generic or biosimilar was  
26 added to the drug formulary at a more favorable coverage tier.

27 (4) The health insurance issuer shall include in the notification how the issuer  
28 is utilizing the rebate provided by the manufacturer of the branded prescription  
29 drug."